Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 1

3(42.9%)

N/A

1(14.3%)

7Total

Phase 2(3)

Phase 1(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05065216Phase 2Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Role: lead

NCT06875141Not ApplicableWithdrawn

DM199 for Pregnancy Complications

Role: lead

NCT03290560Phase 2Completed

Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke

Role: lead

NCT04123613Phase 2Completed

Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)

Role: lead

NCT03795389Phase 1Completed

Study to Assess PK, Safety and Tolerability in Patients With DM and CKD

Role: lead

NCT02868996Phase 1Completed

An Open Label, Phase 1b, Ascending Dose Study of DM199

Role: lead

NCT01845064Phase 1Completed

A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients

Role: lead

All 7 trials loaded